ORYZON Appoints Clinical Development Leader Lori A. Kunkel, M.D., as a Scientific Advisor

MADRID, SPAIN and CAMBRIDGE MA.

• Key reinforcement of Scientific Advisory Board in oncology

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today another key addition to its Scientific Advisory Board (SAB) to reinforce its development capabilities for its epigenetic drug ORY-1001 in leukemia and solid tumors with the appointment of Dr. Lori A. Kunkel.

Click here to see the full Press Release